Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
Abstract
Benign prostatic hyperplasia (BPH) affects the majority of aging men, with medical therapy representing the first-line treatment of lower urinary tract symptoms (LUTS). This article comprehensively examines current medical therapies, their mechanisms, efficacy, and optimal patient selection strategies through a literature review of pivotal clinical trials, systematic reviews, and treatment guidelines from 2000 to 2024. Medical therapy for BPH/LUTS has evolved from symptom management to disease modification, and combination therapy with alpha-1 adrenergic antagonists and 5-alpha reductase inhibitors represents optimal treatment of men with moderate-to-severe symptoms and enlarged prostates (≥30 mL).
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.